Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

ACA vs PUSA: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ACA Wins Head-to-Head Institutional Verdict (5–0 across 6 Pillars · 10–0 Matrix Metrics)

ACA Overall Winner 6-Pillar Tally: ACA 5 – 0 PUSA (1 Tie) Matrix Metrics: ACA 10 – 0 PUSA

As of Nov 20, 2026, Arcosa, Inc. (ACA) is the stronger overall head-to-head candidate over PUSA (PUSA) in the Tradestie Institutional Equity Comparison Engine, winning 10–0 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). ACA carries a Unified Composite Score of 60.0/100 (BUY) at $149.15 (29.1x Forward P/E, 12.3% operating margin), whereas PUSA carries 38.8/100 (SELL) at $1.12 (N/M Forward P/E, N/A operating margin).

  • Technical & Structure Timing Caution: ACA trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 82.2); meanwhile PUSA is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 27.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About ACA vs PUSA
ACA NYSE Head-to-Head Winner
Arcosa, Inc. Common Stock
Fabricated Structural Metal Products
$149.15
+0.08% 1D
Market Cap $7.3B
TTM Revenue $1.19B
Forward P/E 29.1x
Beta / 30D Vol 0.92β · 4% Vol
Unified Composite Score
60.0 / 100 BUY
Tech 56.0 Fund 49.0 Flow 50.0 Mom 36.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (0.5% over 20 days), RSI 82
RSI-14: 82.2 · SMA20: $147.01 · SMA50: $146.08
PUSA US Equity
PUSA
Institutional Equity
$1.12
+0.9% 1D
Market Cap N/A
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.56β · 105% Vol
Unified Composite Score
38.8 / 100 SELL
Tech 25.0 Fund 43.0 Flow 50.0 Mom 59.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -26.7%), weak momentum, RSI 27
RSI-14: 27.2 · SMA20: $1.53 · SMA50: $2.37

6-Pillar Scorecard Institutional Category Breakdown (ACA 5 – 0 PUSA)

Columns: Metric · ACA · PUSA
1. Valuation Multiples ACA
Forward P/E 29.1x N/M
Trailing P/E 36.4x N/M
PEG Ratio 1.86x N/M
EV / Revenue 6.1x N/M
2. Growth & Scale ACA
Revenue Growth (YoY) +1.7% N/A
Earnings Growth (YoY) +448.6% N/A
TTM Revenue (USD) $1.19B N/A
Market Cap $7.3B N/A
3. Profitability & Quality ACA
Gross Margin 22.8% N/A
Operating Margin 12.3% N/A
Net Profit Margin 16.8% N/A
Return on Equity (ROE) 8.0% N/A
4. Balance Sheet & Cash Flow ACA
Cash Generation (TTM) $224M EBITDA N/A
Cash Flow Margin 18.8% EBITDA Mgn N/A
Net Cash / Leverage $60.76 Book/Sh · 8.0% ROE N/A ROE
Dividend Yield 0.14% None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile 28.7% (6th %ile) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markup NEUTRAL · Markdown
6. R&D & Supply-Chain Moat ACA
OpEx & R&D Intensity 10.5% of Rev ($125M) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Engineering & Construction Operator Institutional Equity Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: ACA (10) vs PUSA (0)
Institutional Metric ACA PUSA Criterion Row Edge
Market Capitalization
Scale
$7.3B N/A Larger Scale ACA
Trailing P/E Ratio
Valuation
36.4x N/M Lower Multiple ACA
Forward P/E Ratio
Valuation
29.1x N/M Lower Multiple ACA
Revenue Growth (YoY)
Growth
+1.7% N/A Higher Growth ACA
Operating Margin (TTM)
Profitability
12.3% N/A Higher Margin ACA
Net Profit Margin
Profitability
16.8% N/A Higher Margin ACA
Return on Equity (ROE)
Capital Efficiency
8.0% N/A Higher ROE ACA
52-Week Range Position
Momentum
100% ($91–$149) 2% ($1–$7) Stronger Trend ACA
Beta / 30D Volatility
Risk Regime
0.92β · 4% Vol 1.56β · 105% Vol Lower Realized Risk ACA
Unified Institutional Score
Composite Signal
60.0 / 100 (BUY) 38.8 / 100 (SELL) Higher Composite ACA
Trailing 12M Revenue (USD)
Operating Scale
$1.19B N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
22.8% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
1.86x PEG · 6.1x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$224M EBITDA ($60.76 Book/Sh · 8.0% ROE) N/A (N/A ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon ACA +48.84 pp
ACA: +1.81% · PUSA: -47.03%
3M Horizon ACA +41.99 pp
ACA: +2.86% · PUSA: -39.13%
6M Horizon ACA +76.86 pp
ACA: +22.13% · PUSA: -54.73%
1Y Horizon ACA +76.86 pp
ACA: +22.13% · PUSA: -54.73%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ACA vs PUSA. Trailing 12-month operating profitability (ACA 12.3% vs PUSA N/A) and valuation multiples (ACA 29.1x vs PUSA N/M Forward P/E) are benchmarked directly in Pillar 4 below.

ACA ADR TTM Benchmark FX-Normalized USD
TTM Revenue$1.19B
Gross Margin22.8%
Op. Margin12.3%
ROE / Fwd P/E8.0% · 29.1x
PUSA ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
ACA UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 28.7%
IV Percentile 6th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact ACA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
PUSA UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact PUSA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
ACA Moat Profile Cyclical / Execution-Driven Positioning
Engineering & Construction Operator
Competes within the Engineering & Construction value chain with $7.3B market capitalization and 12.3% operating margin.
OpEx & R&D Reinvestment 10.5% of Rev ($125M)
90D Engineering Disclosures 0 Published
PUSA Moat Profile Cyclical / Execution-Driven Positioning
Institutional Equity Operator
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ ACA vs PUSA Key Questions & Quantitative Answers

As of Nov 20, 2026, Arcosa, Inc. (ACA) is the stronger overall head-to-head candidate over PUSA (PUSA) in the Tradestie Institutional Equity Comparison Engine, winning 10–0 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). ACA carries a Unified Composite Score of 60.0/100 (BUY) at $149.15 (29.1x Forward P/E, 12.3% operating margin), whereas PUSA carries 38.8/100 (SELL) at $1.12 (N/M Forward P/E, N/A operating margin). Technical & Structure Timing Caution: ACA trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 82.2); meanwhile PUSA is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 27.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

ACA leads the Growth & Scale pillar: ACA posts +1.7% YoY revenue growth and +448.6% YoY earnings growth on $1.19B TTM revenue (22.8% gross margin, 12.3% operating margin), compared with PUSA at N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin). On trailing 12-month operating scale, ACA generates $1.19B in USD-normalized revenue versus N/A for PUSA. In operating R&D and SG&A reinvestment, ACA deploys 10.5% of Rev ($125M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for PUSA.

ACA screens cheaper on headline valuation multiples. ACA trades at 29.1x Forward P/E, 36.4x Trailing P/E, 1.86x PEG, and 6.1x EV/Revenue (18.8% EBITDA margin), whereas PUSA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ACA (8.0% ROE) versus PUSA (N/A ROE) capital efficiency.

In options market volatility and institutional positioning, ACA carries 28.7% implied volatility (6th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.92β · 4% Vol realized risk). By comparison, PUSA carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.56β · 105% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.